A pilot study of adjuvant chemotherapy with cisplatin and irinotecan for high-grade pulmonary neuroendocrine carcinona (large cell neuroendocrine carcinoma and small cell lung cancer).

Abstract

7076 Background: Large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer (SCLC) are recognized as high grade neuroendocrine carcinoma (HGNEC) of the lung. In patients with completely resected SCLC, platinum-based adjuvant chemotherapy may be considered. However, the optimum chemotherapy regimen has not been determined. We conducted a multicenter phase II trial to evaluate cisplatin and irinotecan in postoperative adjuvant chemotherapy for the HGNEC. Methods: Patients with completely resected stage IA, IB, IIA, IIB or stage IIIA HGNEC received 4 cycles of cisplatin (60 mg/m2, day 1) plus irinotecan (60 mg/m2, day 1, 8, 15). This regimen was repeated every 4 weeks. Other eligibility criteria included ECOG PS 0–1, age 20, and <75 years old, adequate organ function, no prior chemotherapy or radiotherapy. Patients with UGT1A1 polymorphisms (homozygous for *6 or *28, simultaneously heterozygous *6 and *28), associated with irinotecan-related severe toxicity, were excluded. The primary endpoint wa...